Oncology Research Program

Highlights of the NCCN Oncology Research Program

The NCCN Oncology Research Program (ORP) strives to improve the quality of life for patients and reduce cancer-related deaths by advancing cancer therapies through research. Since the program's establishment in 1999, the NCCN ORP has brought millions of dollars in research grants to investigators at NCCN Member Institutions. Research grants are provided to NCCN through collaborations with pharmaceutical and biotechnology companies; these grants are in turn used to support scientifically meritorious cancer research efforts.

NCCN ORP studies typically explore new avenues of clinical investigation and seek answers to important cancer-related questions. All studies are approved and funded through a scientific peer-review process and are overseen by the ORP.

An NCCN study funded through the grant mechanism is highlighted below.

Carfilzomib Plus Belinostat in Relapsed/Refractory Non-Hodgkin's Lymphoma Subtypes: A Phase I Study

Principal Investigator: Jeremy S. Abramson, MD

Conditions: Diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, peripheral T-cell lymphomas

Institutions: Massachusetts General Hospital Cancer Center and Dana-Farber Cancer Institute

This is a phase I, open-label, dose-escalation study of carfilzomib in combination with belinostat for relapsed or refractory non-Hodgkin's lymphoma (NHL). Four dose levels are planned. Dose-escalation will be performed in a traditional 3+3 design. The trial is currently accruing at the maximum dose level. Ten additional patients will be accrued at the maximum tolerated dose (MTD). Cycle length is 28 days. Carfilzomib will be administered by intravenous bolus on days 1–2, 8–9, and 15–16. Beginning with dose level 1, the carfilzomib will be dose-escalated with cycle 2. Belinostat will be administered by intravenous bolus on days 1–5. Subjects who are tolerating therapy and are without progressive disease may receive treatment until progression.

Primary Objective:

  • Determine the MTD of carfilzomib and belinostat in combination

Secondary Objectives:

  • Establish the toxicity profile of carfilzomib combined with belinostat

  • Evaluate pharmacokinetics effects of carfilzomib and belinostat in combination

  • Preliminary assessment of efficacy of carfilzomib and belinostat in NHL

Contact: Jeremy S. Abramson, MD • 617-724-4000 • jabramson@mgh.harvard.edu

ClinicalTrials.gov Identifier: NCT02142530

The goal of the Highlights of the NCCN Oncology Research Program (ORP) is to provide readers with more information on the ORP, including studies currently accruing patients.

For more information on specific trials, including patient selection criteria, please use the contact information listed with each study.

For more information on the NCCN ORP, including a complete detailing of the clinical studies currently underway at NCCN Member Institutions, please access the NCCN ORP pages at NCCN.org/clinical_trials/clinicians.asp.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Article Sections

Article Information

PubMed


Google Scholar

Related Articles

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 25 25 0
PDF Downloads 1 1 0
EPUB Downloads 0 0 0